Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer

Cancer Chemotherapy and Pharmacology
Eun Kyung ChoJin-Hyoung Kang

Abstract

The aim of this study was to compare CKD-810 (test docetaxel) with Taxotere(®) (reference docetaxel) in terms of pharmacokinetics and safety for patients with advanced or metastatic carcinoma. A randomized, open-label, two-way crossover study was conducted in eligible patients. Patients received with reference or test drugs of 75 mg/m(2) docetaxel by intravenous infusion for 60 min in the first period and the alternative drug in the second period with a washout of 3 weeks. Plasma concentrations of docetaxel were determined by validated high-performance liquid chromatography coupled to tandem mass spectrometry detection. Pharmacokinetic parameters, including the maximum plasma concentration (C(max)) and the area under the concentration-time curve (AUC), were determined by non-compartmental analysis. A total of 44 patients were included in the study, 21 patients received test drug and 23 received reference drug for the first cycle. The C(max) of docetaxel was 2,658.77 ng/mL for test drug and 2,827.60 ng/mL for reference drug, and two drugs showed no difference with a statistical significance. Time to reach C(max) (T(max)) of CKD-810 (0.94 h) versus reference docetaxel (0.97 h) was also not significantly different. Other pharmacok...Continue Reading

References

Feb 20, 1991·Journal of the National Cancer Institute·I Ringel, S B Horwitz
Mar 1, 1991·Journal of Medicinal Chemistry·F Guéritte-VoegeleinP Potier
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S B Kaye
Dec 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V ValeroG N Hortobagyi
Feb 1, 1996·Journal of Clinical Periodontology·T TervahartialaT Sorsa
Jul 1, 1997·Contact Dermatitis·M BerghA T Karlberg
Feb 9, 2000·Cancer Chemotherapy and Pharmacology·H RosingJ H Beijnen
Apr 25, 2000·American Journal of Clinical Oncology·V FerraresiF Cognetti
May 31, 2001·Journal of Pharmacokinetics and Pharmacodynamics·S C Chow, H Wang
Nov 13, 2001·British Journal of Pharmacology·M MarkW H Reinhart
Jul 11, 2002·Cancer Chemotherapy and Pharmacology·Pierre MarchettiniPaul H Sugarbaker
Oct 10, 2003·Clinical Pharmacology and Therapeutics·Walter J LoosAlex Sparreboom
Feb 26, 2004·Bioorganic & Medicinal Chemistry·Emmanuel BouvierClaude Monneret
Apr 15, 2004·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Weiying HouHoward L McLeod
Jan 8, 2005·Clinical Pharmacology and Therapeutics·Sharyn D BakerAlex Sparreboom
Aug 5, 2006·International Journal of Pharmaceutics·T MusumeciG Puglisi
Dec 13, 2006·Anti-cancer Drugs·Frederike K EngelsJaap Verweij
Jan 20, 2007·Journal of Biomedical Materials Research. Part a·Mi YangBaorui Liu
Jul 13, 2007·Bioorganic & Medicinal Chemistry·Wenting DuYongzhou Hu
Aug 23, 2008·Drug Development and Industrial Pharmacy·Elise BracqMichel Guerbet
Feb 24, 2009·Journal of Pharmaceutical and Biomedical Analysis·Ling ZhaoYu Yu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.